Encore Capital Group (NASDAQ:ECPG) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Encore Capital Group is a leading provider of debt management and recovery solutions for consumers and property owners across a broad range of assets. Through its subsidiaries, the company purchases portfolios of consumer receivables from major banks, credit unions, and utility providers, and partners with individuals as they repay their obligations and work toward financial recovery. Through its Propel Financial Services subsidiary, the company assists property owners who are delinquent on their property taxes by structuring affordable monthly payment plans. Encore’s success and future growth are driven by its sophisticated and widespread use of analytics, its broad investments in data and behavioral science, the significant cost advantages provided by its highly-efficient operating model and proven investment strategy, and the company’s demonstrated commitment to conducting business ethically and in ways that support its consumers’ financial recovery. “
Top Growth Stocks To Buy Right Now: ImmunoGen, Inc.(IMGN)
- [By Shane Hupp]
ImmunoGen, Inc. (NASDAQ:IMGN) was the target of unusually large options trading activity on Thursday. Stock investors purchased 2,024 put options on the stock. This is an increase of 816% compared to the typical volume of 221 put options.
- [By Shane Hupp]
News coverage about ImmunoGen (NASDAQ:IMGN) has trended somewhat positive on Monday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmunoGen earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.3285082790906 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
- [By Brian Orelli]
ImmunoGen (NASDAQ:IMGN) is in waiting mode with its lead drug, mirvetuximab, being tested in the phase 3 Forward I trial in patients with ovarian cancer, making for a relatively quiet first-quarter earnings release.
- [By Stephan Byrd]
Shares of ImmunoGen, Inc. (NASDAQ:IMGN) rose 6.6% during trading on Thursday . The stock traded as high as $11.08 and last traded at $11.04. Approximately 3,157,358 shares changed hands during trading, an increase of 3% from the average daily volume of 3,064,728 shares. The stock had previously closed at $10.36.
Top Growth Stocks To Buy Right Now: Prudential Public Limited Company(PUK)
- [By Stephan Byrd]
Here are some of the news headlines that may have effected Accern’s rankings:
Get Prudential alerts:
Zacks Investment Research Lowers Prudential (PUK) to Hold (americanbankingnews.com) Financial wellness program popularity rises among employers, up 63 percentage points in two years (markets.financialcontent.com) FY2018 EPS Estimates for Prudential (PUK) Reduced by Jefferies Group (americanbankingnews.com) Jefferies Group Weighs in on Prudential’s FY2020 Earnings (PUK) (americanbankingnews.com) ValuEngine Downgrades Prudential (PUK) to Hold (americanbankingnews.com)
Shares of PUK stock traded down $0.02 during trading on Tuesday, hitting $51.56. 141,455 shares of the stock traded hands, compared to its average volume of 198,097. The firm has a market cap of $66.49 billion, a PE ratio of 13.79, a PEG ratio of 1.34 and a beta of 1.55. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.03 and a current ratio of 0.03. Prudential has a 52-week low of $44.49 and a 52-week high of $55.36.
- [By Ethan Ryder]
ValuEngine lowered shares of Prudential (NYSE:PUK) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.
Several other analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Prudential from a hold rating to a buy rating and set a $57.00 target price on the stock in a research note on Tuesday, March 27th. Berenberg Bank cut shares of Prudential from a hold rating to a sell rating in a research note on Thursday, March 29th. Finally, Citigroup cut shares of Prudential from a buy rating to a neutral rating in a research note on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $57.00.
- [By Ethan Ryder]
Prudential (NYSE: PUK) and Reinsurance Group of America (NYSE:RGA) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Top Growth Stocks To Buy Right Now: Phillips 66 Partners LP(PSXP)
- [By Logan Wallace]
Get a free copy of the Zacks research report on Phillips 66 Partners (PSXP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Matthew DiLallo]
One of the drivers of that increase is the fact that Diamondback Energy has secured 50,000 BPD of capacity on the Gray Oak Pipeline, which is under development by Phillips 66 Partners (NYSE:PSXP) and Andeavor (NYSE:ANDV). Initially envisioned as a 385,000 BPD pipeline, Gray Oak will now be a 700,000 BPD pipeline that its developers could expand to 1 million BPD if they secure enough customers. Phillips 66 Partners, which is leading the development, expects the project to enter service by the end of 2019.
- [By Reuben Gregg Brewer]
In the roughly five years since Phillips 66 Partners LP (NYSE:PSXP) has been publicly traded, its enterprise value has increased dramatically, going from around $2.5 billion to nearly $9.5 billion. But things are changing and the midstream partnership’s future growth isn’t likely to look like its past growth. Here are three challenges facing high-yielding Phillips 66 Partners as it looks to move into a new stage of its corporate life.